Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Taha Merghoub

Showing results (111-120 of 216) with videos related to

Pageof 22
Sort By:
Nature Nanotechnology|December 30, 2025
An ultrasmall core-shell silica nanoparticle improves antitumour immunity and survival by remodelling suppressive melanoma microenvironmentsGabriel De Leon, Li Zhang, Nabil A Siddiqui, et al.
Oncotarget|June 22, 2016
The metabolic/pH sensor soluble adenylyl cyclase is a tumor suppressor proteinLavoisier Ramos-Espiritu, Ana Diaz, Charlee Nardin, et al.
Cancer Cell|October 10, 2018
Non-conventional Inhibitory CD4<sup>+</sup>Foxp3<sup>-</sup>PD-1<sup>hi</sup> T Cells as a Biomarker of Immune Checkpoint Blockade ActivityRoberta Zappasodi, Sadna Budhu, Matthew D Hellmann, et al.
The Journal of Experimental Medicine|May 5, 2023
OX40L-expressing recombinant modified vaccinia virus Ankara induces potent antitumor immunity via reprogramming TregsNing Yang, Yi Wang, Shuaitong Liu, et al.
NPJ Breast Cancer|April 20, 2022
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/- trastuzumab in patients with breast cancer brain metastasesDavid B Page, Kathryn Beal, Stefanie N Linch, et al.
Cancer Cell|November 17, 2012
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomasPiro Lito, Christine A Pratilas, Eric W Joseph, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 2, 2022
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid TumorsDiwakar Davar, Roberta Zappasodi, Hong Wang, et al.
Urologic Oncology|May 21, 2026
Effective PD-1 checkpoint blockade in bladder cancer model requires tumor-draining lymph nodes and lymphocyte traffickingJuan C Angulo-Lozano, Lina Posada-Calderon, Huixian Liu, et al.
Cancer Discovery|March 5, 2014
Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignanciesOmar Abdel-Wahab, Virginia M Klimek, Alisa A Gaskell, et al.
JCO Precision Oncology|September 11, 2020
<i>PTEN</i> Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic MelanomaFederica Catalanotti, Donavan T Cheng, Alexander N Shoushtari, et al.
Pageof 22

Showing results (111-120 of 216) with videos related to

Sort By:
Pageof 22
Nature Nanotechnology|December 30, 2025
An ultrasmall core-shell silica nanoparticle improves antitumour immunity and survival by remodelling suppressive melanoma microenvironmentsGabriel De Leon, Li Zhang, Nabil A Siddiqui, et al.
Oncotarget|June 22, 2016
The metabolic/pH sensor soluble adenylyl cyclase is a tumor suppressor proteinLavoisier Ramos-Espiritu, Ana Diaz, Charlee Nardin, et al.
Cancer Cell|October 10, 2018
Non-conventional Inhibitory CD4<sup>+</sup>Foxp3<sup>-</sup>PD-1<sup>hi</sup> T Cells as a Biomarker of Immune Checkpoint Blockade ActivityRoberta Zappasodi, Sadna Budhu, Matthew D Hellmann, et al.
The Journal of Experimental Medicine|May 5, 2023
OX40L-expressing recombinant modified vaccinia virus Ankara induces potent antitumor immunity via reprogramming TregsNing Yang, Yi Wang, Shuaitong Liu, et al.
NPJ Breast Cancer|April 20, 2022
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/- trastuzumab in patients with breast cancer brain metastasesDavid B Page, Kathryn Beal, Stefanie N Linch, et al.
Cancer Cell|November 17, 2012
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomasPiro Lito, Christine A Pratilas, Eric W Joseph, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 2, 2022
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid TumorsDiwakar Davar, Roberta Zappasodi, Hong Wang, et al.
Urologic Oncology|May 21, 2026
Effective PD-1 checkpoint blockade in bladder cancer model requires tumor-draining lymph nodes and lymphocyte traffickingJuan C Angulo-Lozano, Lina Posada-Calderon, Huixian Liu, et al.
Cancer Discovery|March 5, 2014
Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignanciesOmar Abdel-Wahab, Virginia M Klimek, Alisa A Gaskell, et al.
JCO Precision Oncology|September 11, 2020
<i>PTEN</i> Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic MelanomaFederica Catalanotti, Donavan T Cheng, Alexander N Shoushtari, et al.
Pageof 22